DXSP DXS International PLC

DXS International plc (AQSE:DXSP): ExpertCare featured in Innovate UK Research Project

DXS International plc (AQSE:DXSP): ExpertCare featured in Innovate UK Research Project

DXS INTERNATIONAL PLC (AQSE: DXSP)

ExpertCare featured in Innovate UK Research Project

DXS International plc ("DXS" or "the Company"), a leading provider of digital clinical decision support solutions, is thrilled to announce that its leading-edge digital health solution, ExpertCare, has been independently reviewed by the prestigious York Health Economics Consortium (YHEC) with results that confirm its powerful impact on both clinical outcomes and NHS cost-efficiency. 

Funded by DXS and Innovate UK and delivered in partnership with Health Innovation East, the evaluation assessed ExpertCare’s effectiveness in supporting medicines optimisation for patients with hypertension. The study, involving 2,484 patients across 13 UK GP practices, compared ExpertCare against standard hypertension review for GP practices. 

The evaluation found that ExpertCare delivers more effective hypertension control, reduces treatment variability, and is cost-saving in both the short and long term. 

The YHEC report concluded that: 

  • ExpertCare significantly increases the number of patients with optimally managed hypertension. 
  • For every £1 invested, ExpertCare returns £2.70 to the NHS. 

ExpertCare functions as an intelligent clinical decision support tool, streamlining data collection and generating treatment recommendations aligned with NICE guidelines—freeing up clinical time and improving outcomes at scale. 

David Immelman, CEO of DXS, commented: 

“We are incredibly proud of the results of this independent validation. It affirms our belief that ExpertCare has the potential to materially improve hypertension management across England, while reducing the cost burden on the NHS. These results highlight the real-world value of deploying ExpertCare nationally starting from year one.” 

For more information, please visit  

Contacts:

David Immelman



DXS International plc



-systems.com



 
01252 719800
AQSE Corporate Broker and Corporate Advisor



Hybridan LLP



Claire Louise Noyce
020 3764 2341

Notes to Editors

About DXS:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.

Attachment



EN
10/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DXS International PLC

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Research: DXS International PLC

Good Afternoon, DXS International PLC (AQSE:DXSP) announced Interims to 31 October 2025. We have published research on this which is attached and a snapshot of the research is below.

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Small Cap Feast: 28 January 2026

28th January 2026 @HybridanLLP Our daily digest of news from UK Small Caps * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: Following a Reverse Tak...

 PRESS RELEASE

DXS International plc (AQSE: DXSP): Half-year Financial Report

DXS International plc (AQSE: DXSP): Half-year Financial Report DXS INTERNATIONAL PLC (AQSE: DXSP) HALF YEAR RESULTS DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to provide shareholders with its unaudited interim results for the half year ending 31 October 2025. H1 2025 Financial highlights: Core recurring revenue model remains resilient. Revenue decreased by 2.6% to £1,684,712 (H1 2024 - £1,730,829) in the six months to 31 October 2025 ("Period"). Administration costs decreased by 5% in the Period (H1 2024 -£87,474)Loss afte...

 PRESS RELEASE

DXS International plc (AQSE: DXSP) Update on Cyber Security Incident

DXS International plc (AQSE: DXSP) Update on Cyber Security Incident 24 December 2025 DXS INTERNATIONAL PLC (AQSE: DXSP) Update on Cyber Security Incident The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, would like to provide an update on the security incident that affected its office servers, which was reported via RNS on 18 December. The incident has been contained, and DXS remains vigilant by implementing additional monitoring and security measures.  The Director...

 PRESS RELEASE

DXS INTERNATIONAL PLC (AQSE: DXSP) Result of AGM

DXS INTERNATIONAL PLC (AQSE: DXSP) Result of AGM 19 December 2025 DXS INTERNATIONAL PLC (AQSE: DXSP) Result of DXS AGM 2025 The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce that all resolutions put to shareholders at the Company's Annual General Meeting ("AGM") held yesterday were duly passed. All resolutions were passed on a poll and the votes received from shareholders on each resolution put to the AGM are set out below. ResolutionVotes For *...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch